Compare MKTW & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | VERU |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 41.7M |
| IPO Year | N/A | N/A |
| Metric | MKTW | VERU |
|---|---|---|
| Price | $14.50 | $2.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $20.00 | ★ $22.50 |
| AVG Volume (30 Days) | 12.1K | ★ 106.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.08 | $2.10 |
| 52 Week High | $21.74 | $7.40 |
| Indicator | MKTW | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 48.27 |
| Support Level | $13.92 | $2.22 |
| Resistance Level | $15.79 | $2.50 |
| Average True Range (ATR) | 0.65 | 0.19 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 19.05 | 31.67 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.